SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Barthel H) "

Sökning: WFRF:(Barthel H)

  • Resultat 1-10 av 32
  • [1]234Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Shulevski, A., et al. (författare)
  • The peculiar radio galaxy 4C 35.06 : a case for recurrent AGN activity?
  • 2015
  • Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 579, s. 1-10
  • Tidskriftsartikel (refereegranskat)abstract
    • Using observations obtained with the LOw Fequency ARray (LOFAR), the Westerbork Synthesis Radio Telescope (WSRT) and archival Very Large Array (VLA) data, we have traced the radio emission to large scales in the complex source 4C 35.06 located in the core of the galaxy cluster Abell 407. At higher spatial resolution (~ 4″), the source was known to have two inner radio lobes spanning 31 kpc and a diffuse, low-brightness extension running parallel to them, offset by about 11 kpc (in projection). At 62 MHz, we detect the radio emission of this structure extending out to 210 kpc. At 1.4 GHz and intermediate spatial resolution (~ 30″), the structure appears to have a helical morphology. We have derived the characteristics of the radio spectral index across the source. We show that the source morphology is most likely the result of at least two episodes of AGN activity separated by a dormant period of around 35 Myr. The outermost regions of radio emission have a steep spectral index (α< − 1), indicative of old plasma. We connect the spectral index properties of the resolved source structure with the integrated fluxdensity spectral index of 4C 35.06 and suggest an explanation for its unusual integrated flux density spectral shape (a moderately steep power law with no discernible spectral break), possibly providing a proxy for future studies of more distant radio sources through inferring their detailed spectral index properties and activity history from their integrated spectral indices. The AGN is hosted by one of the galaxies located in the cluster core of Abell 407. We propose that it is intermittently active as it moves in the dense environment in the cluster core. In this scenario, the AGN turned on sometime in the past, and has produced the helical pattern of emission, possibly a sign of jet precession/merger during that episode of activity. Using LOFAR, we can trace the relic plasma from that episode of activity out to greater distances from the core than ever before. Using the the WSRT, we detect H I in absorption against the center of the radio source. The absorption profile is relatively broad (FWHM of 288 kms-1), similar to what is found in other clusters. The derived column density is NHI ~ 4 × 1020 cm-2 for a Tspin = 100 K. This detection supports the connection – already suggested for other restarted radio sources – between the presence of cold gas and restarting activity. The cold gas appears to be dominated by a blue-shifted component although the broad H I profile could also include gas with different kinematics. Understanding the duty cycle of the radio emission as well as the triggering mechanism for starting (or restarting) the radio-loud activity can provide important constraints to quantify the impact of AGN feedback on galaxy evolution. The study of these mechanisms at low frequencies using morphological and spectral information promises to bring new important insights in this field.
  •  
2.
  • Sehlin, Dag, 1976-, et al. (författare)
  • Engineered antibodies : new possibilities for brain PET?
  • 2019
  • Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : SPRINGER. - 1619-7070 .- 1619-7089. ; 46:13, s. 2848-2858
  • Forskningsöversikt (refereegranskat)abstract
    • Almost 50 million people worldwide are affected by Alzheimer's disease (AD), the most common neurodegenerative disorder. Development of disease-modifying therapies would benefit from reliable, non-invasive positron emission tomography (PET) biomarkers for early diagnosis, monitoring of disease progression, and assessment of therapeutic effects. Traditionally, PET ligands have been based on small molecules that, with the right properties, can penetrate the blood-brain barrier (BBB) and visualize targets in the brain. Recently a new class of PET ligands based on antibodies have emerged, mainly in applications related to cancer. While antibodies have advantages such as high specificity and affinity, their passage across the BBB is limited. Thus, to be used as brain PET ligands, antibodies need to be modified for active transport into the brain. Here, we review the development of radioligands based on antibodies for visualization of intrabrain targets. We focus on antibodies modified into a bispecific format, with the capacity to undergo transferrin receptor 1 (TfR1)-mediated transcytosis to enter the brain and access pathological proteins, e.g. amyloid-beta. A number of such antibody ligands have been developed, displaying differences in brain uptake, pharmacokinetics, and ability to bind and visualize the target in the brain of transgenic mice. Potential pathological changes related to neurodegeneration, e.g. misfolded proteins and neuroinflammation, are suggested as future targets for this novel type of radioligand. Challenges are also discussed, such as the temporal match of radionuclide half-life with the ligand's pharmacokinetic profile and translation to human use. In conclusion, brain PET imaging using bispecific antibodies, modified for receptor-mediated transcytosis across the BBB, is a promising method for specifically visualizing molecules in the brain that are difficult to target with traditional small molecule ligands.
  •  
3.
  • Bailey, D. L., et al. (författare)
  • Combined PET/MRI : Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tubingen, Germany
  • 2018
  • Ingår i: Molecular Imaging and Biology. - : SPRINGER. - 1536-1632 .- 1860-2002. ; 20:1, s. 4-20
  • Forskningsöversikt (refereegranskat)abstract
    • The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tubingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.
  •  
4.
  • Chételat, Gaël, et al. (författare)
  • Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
  • 2020
  • Ingår i: The Lancet Neurology. - : Lancet Ltd. - 1474-4422 .- 1474-4465. ; 19:11, s. 951-962
  • Forskningsöversikt (refereegranskat)abstract
    • Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.
  •  
5.
  • Karlson, A. M. L., et al. (författare)
  • Nitrogen fixation by cyanobacteria stimulates production in Baltic food webs
  • 2015
  • Ingår i: Ambio. - 0044-7447 .- 1654-7209. ; 44, s. S413-S426
  • Tidskriftsartikel (refereegranskat)abstract
    • Filamentous, nitrogen-fixing cyanobacteria form extensive summer blooms in the Baltic Sea. Their ability to fix dissolved N-2 allows cyanobacteria to circumvent the general summer nitrogen limitation, while also generating a supply of novel bioavailable nitrogen for the food web. However, the fate of the nitrogen fixed by cyanobacteria remains unresolved, as does its importance for secondary production in the Baltic Sea. Here, we synthesize recent experimental and field studies providing strong empirical evidence that cyanobacterial nitrogen is efficiently assimilated and transferred in Baltic food webs via two major pathways: directly by grazing on fresh or decaying cyanobacteria and indirectly through the uptake by other phytoplankton and microbes of bioavailable nitrogen exuded from cyanobacterial cells. This information is an essential step toward guiding nutrient management to minimize noxious blooms without overly reducing secondary production, and ultimately most probably fish production in the Baltic Sea.
  •  
6.
  •  
7.
  • Jansen, Willemijn J, et al. (författare)
  • Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
  • 2018
  • Ingår i: JAMA psychiatry. - : American Medical Association. - 2168-6238 .- 2168-622X. ; 75:1, s. 84-95
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years.Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.
  •  
8.
  • Bailey, D. L., et al. (författare)
  • Combined PET/MRI : from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tubingen, Germany
  • 2016
  • Ingår i: Molecular Imaging and Biology. - 1536-1632 .- 1860-2002. ; 18:5, s. 637-650
  • Tidskriftsartikel (refereegranskat)abstract
    • This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tubingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 32
  • [1]234Nästa
Typ av publikation
tidskriftsartikel (24)
forskningsöversikt (4)
rapport (2)
annan publikation (1)
konferensbidrag (1)
Typ av innehåll
refereegranskat (27)
övrigt vetenskapligt (5)
Författare/redaktör
Barthel, H. (12)
Drzezga, A (7)
Nordberg, A (6)
Hansson, O. (5)
Conway, John, 1963 (5)
Sabri, O (5)
visa fler...
Rottgering, H. (5)
Drzezga, Alexander (5)
Ossenkoppele, R (5)
Lehnert, M. (5)
Brüggen, M. (5)
Morganti, R. (5)
Garibotto, V. (5)
Law, I. (5)
Brunetti, G (5)
Zetterberg, Henrik, ... (4)
Scheltens, P (4)
Nordberg, Agneta (4)
Frisoni, Giovanni B. (4)
de Gasperin, F. (4)
Rabinovici, Gil D (4)
Villemagne, Victor L (4)
Morbelli, S (4)
Jansen, Willemijn J. (4)
Tijms, Betty M (4)
Brooks, David J (4)
Blennow, Kaj, 1958 (3)
Jagust, William J. (3)
Hansson, Oskar (3)
Scheltens, Philip (3)
van der Flier, Wiesj ... (3)
Rinne, Juha O. (3)
Ferrari, C (3)
Ossenkoppele, Rik (3)
Barthel, S. (3)
Verbeek, Marcel M (3)
Chetelat, G (3)
Heald, G. (3)
Orru, E. (3)
Pizzo, R. (3)
Bonafede, A. (3)
Hoeft, M. (3)
Tasse, C. (3)
Rowe, Christopher C (3)
Boellaard, R. (3)
Fagan, Anne M (3)
de Mendonça, Alexand ... (3)
Wallin, Åsa K. (3)
Shulevski, A. (3)
Herholz, K (3)
visa färre...
Lärosäte
Karolinska Institutet (10)
Göteborgs universitet (8)
Chalmers tekniska högskola (6)
Uppsala universitet (3)
Stockholms universitet (3)
Umeå universitet (2)
visa fler...
Örebro universitet (2)
Kungliga Tekniska Högskolan (1)
Lunds universitet (1)
Linnéuniversitetet (1)
Högskolan i Gävle (1)
Naturhistoriska riksmuseet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (31)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (12)
Medicin och hälsovetenskap (9)
Teknik (3)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy